Abstract
* The FDA has approved the new drug rufinamide (Banzel) for adjunctive use in the treatment of Lennox-Gastaut syndrome, a rare and severe form of epilepsy.
* The most common adverse effects include somnolence, fatigue, ataxia and disturbance of gait, dizziness, nausea, vomiting, and blurred or double vision.